Actively Recruiting
Evaluation of an Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PANTHEON)
Led by Montreal Heart Institute · Updated on 2026-03-10
2570
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the best antiplatelet treatment for patients who have had a myocardial infarction (heart attack) and are treated medically without revascularization procedures. This trial, called PANTHEON, focuses on whether taking ticagrelor alone can reduce bleeding events compared to the standard treatment of combining ticagrelor with aspirin for 12 months. The study aims to balance the risks of bleeding with the risks of ischemic events in this vulnerable patient group, which represents a large portion of heart attack cases in North America. Participants will be randomly assigned to receive either ticagrelor alone (90 mg twice daily plus a placebo once daily) or dual antiplatelet therapy (ticagrelor 90 mg twice daily combined with aspirin 80 mg once daily) for one year. This phase 3 trial uses a quadruple masking method to fairly compare the treatments. The study will monitor patients from the time of randomization through 12 months to assess bleeding events and ischemic outcomes. During the trial, participants will attend scheduled study visits where researchers will evaluate bleeding events classified by the BARC system and ischemic events such as death, heart attack, stroke, or need for coronary procedures. The trial will also assess safety and effectiveness measures, including individual components of the primary outcomes. Patient adherence and clinical status will be carefully monitored throughout the 12-month treatment period.
CONDITIONS
Brief Title
Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Hospitalized for type 1 myocardial infarction according to the 4th Universal Definition of MI
- Coronary angiogram performed
- Planned for medical management without revascularization
- Willingness to participate and attend study visits
- Expected life expectancy of at least 12 months
You will not qualify if you...
- Hospitalized for type 2-5 myocardial infarction or unstable angina
- Hospitalized for STEMI with acute thrombotic lesion of a major epicardial vessel
- Cardiac biomarker elevations not believed to be ischemic in origin
- Confirmed or suspected spontaneous coronary artery dissection
- Need for chronic oral anticoagulant therapy
- Need for dual antiplatelet therapy for non-coronary reasons
- Use of non-trial antiplatelet drugs that must be continued
- Previous hospitalization for MI, PCI, or CABG within 12 months
- Known allergy or intolerance to aspirin or ticagrelor
- Unsuitability for study treatments based on physician judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive ticagrelor monotherapy or dual antiplatelet therapy with ticagrelor and aspirin to manage their myocardial infarction.
Trial Site Locations
Total: 1 location
1
Montreal Heart Institute
Montreal, Quebec, Canada, H1Y2P3
Actively Recruiting
Research Team
G
Guillaume Marquis-Gravel, MD
R
Roseline Therrien
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here